RAS mutations are the most common oncogenic drivers across human cancers, but there remains a paucity of clinically-validated pharmacological inhibitors of RAS, as druggable pockets have proven ...

Targeting specific protein–protein interactions (PPIs) is an attractive concept for drug development, but hard to implement since intracellular antibodies do not penetrate cells and most ...

Each year, more than 3 million people are diagnosed with cancers driven by mutations in three RAS-family genes: KRAS, NRAS, and HRAS. RAS-family mutations are associated with numerous types of cancer.

The targeted RAS inhibitor daraxonrasib was found to be safe and showed signs of efficacy in patients with previously treated RAS-mutant metastatic pancreatic cancer, according to a Phase I/II ...

Ras genes encode proteins that can cause cancer (or become oncogenic) when mutated. All Ras proteins are GTPases which act as molecular switches in the cell, regulating signaling pathways and other ...